Pandemic bites but Sanofi stays buoyant in second quarter

29 July 2020

Despite second quarter 2020 sales being undercut by the coronavirus pandemic, French drugs and vaccines specialist Sanofi (Euronext: SAN) has raised its projection for the year, spurred by cost cutting measures and the sale of its stake in Regeneron Pharmaceuticals (Nasdaq: REGN).

Exchange rate movements in the firm’s South American operations also knocked the wind out of sales, which were down 4.9% at 8.2 billion euros ($9.6 billion) for the quarter.

Business earnings per share (EPS), a non-Generally Accepted Accounting Principles (GAAP) measure, hit 1.28 euros, an increase of 3.2%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK